SCHEMBL3303489

SCHEMBL3303489

CC(=O)c1ccc2c(c1)[C@H](NC(=O)c1ccccc1)[C@H](O)C(C)(C)O2

nearest known ligand 0.81

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ABCC9 O60706 5/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8343026 1.00 ABCC9 (0.64) ABCC9
SCHEMBL8343023 1.00 ABCC9 (0.64) ABCC9
SCHEMBL7722209 1.00 ABCC9 (0.64) ABCC9
SCHEMBL8343672 0.91 ABCC9 (0.64) ABCC9
SCHEMBL8343667 0.91 ABCC9 (0.64) ABCC9
SCHEMBL8338365 0.91 ABCC9 (0.64) ABCC9
Carabersat SCHEMBL9287969 0.89 ABCC9 (0.62) ABCC9
SCHEMBL8338373 0.89 ABCC9 (0.73) ABCC9
Carabersat SCHEMBL3308650 0.89 ABCC9 (0.62) ABCC9
Carabersat SCHEMBL3300409 0.89 ABCC9 (0.62) ABCC9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100099752-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC. (GB) 2010-04-22 US claimed
US-20070088064-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC 2007-04-19 US claimed
US-20030236410-A1 Pharmaceutical composition containing bicyclic type compounds SMITHKLINE BEECHAM P.L.C. 2003-12-25 US claimed
US-20020123630-A1 Pharmaceutical composition containing bicyclic type compounds SMITHKLINE BEECHAM P.L.C. 2002-09-05 US claimed
US-20010021780-A1 Pharmaceutical composition containing bicyclic type compounds SMITHKLINE BEECHAM P.L.C. 2001-09-13 US claimed
EP-0673374-B1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 2000-03-01 EP claimed
US-5948811-A Pharmaceutical composition containing bicyclic type compounds SMITHKLINE BEEGHAM P.L.C. (GB) 1999-09-07 US claimed
WO-1994013657-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 1994-06-23 WO claimed
US-20100099752-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC. (GB) 2010-04-22 US disclosed
US-20070088064-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC 2007-04-19 US disclosed
US-20030236410-A1 Pharmaceutical composition containing bicyclic type compounds SMITHKLINE BEECHAM P.L.C. 2003-12-25 US disclosed
US-20020123630-A1 Pharmaceutical composition containing bicyclic type compounds SMITHKLINE BEECHAM P.L.C. 2002-09-05 US disclosed
US-20010021780-A1 Pharmaceutical composition containing bicyclic type compounds SMITHKLINE BEECHAM P.L.C. 2001-09-13 US disclosed
EP-0673374-B1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 2000-03-01 EP disclosed
US-5948811-A Pharmaceutical composition containing bicyclic type compounds SMITHKLINE BEEGHAM P.L.C. (GB) 1999-09-07 US disclosed
WO-1994013657-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 1994-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236410-A1 Pharmaceutical composition containing bicyclic type compounds CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2B6 ABCC9 162/4885
US-20070088064-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CFH, CBR3 ABCC9 155/4885
US-20010021780-A1 Pharmaceutical composition containing bicyclic type compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CLIC1, NAF1 ABCC9 122/4885
US-20100099752-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SNCA, GRIN2C, PYGB ABCC9 1314/4885
US-20020123630-A1 Pharmaceutical composition containing bicyclic type compounds CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CFH ABCC9 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.